In addition, the strong influence of copy-number gains on levels of expression of FADD confounds both eQTL and DSS analyses with opposite effects; excluding 119 ER+ cancers with copy-number gains strengthens the eQTL association in TCGA (Fig. 5c), excluding 345 such samples from the analysis of outcome in Metabric abrogates the association with DSS (Fig. 5d), suggesting that samples with copy-number gains at this region may have a poor outcome that is not directly related to levels of expression of FADD. Similarly, for CDCA7 the associations are inconsistent. The gene discussed is CDCA7; the disease is cancer.